Department of Ophthalmology, University of Florida-Jacksonville, Jacksonville, Florida 32209, USA.
J Ocul Pharmacol Ther. 2009 Dec;25(6):507-11. doi: 10.1089/jop.2009.0028.
To evaluate in vitro the effects of bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, on retinal pigment epithelial cells (RPE) and retinal ganglion cells (RGC), at doses that were inhibitory to VEGF-enriched choroidal endothelial cells (CEC).
Monkey CEC (RF6A), human RPE cells (ARPE-19), and rat RGC (RGC-5) were exposed for 24 h to increasing doses of bevacizumab. Cell numbers were quantified with WST-1 assay. Cell death was assessed using propidium iodide (PI) staining via flow cytometry and fluorescent microscopy.
Bevacizumab was inhibitory to RF6A at 2.0 mg/mL (P < 0.005). No effect on cell viability was noted on ARPE-19 and RGC-5 cell lines at this particular dose of bevacizumab. These results were supported by fluorescent microscopy of PI-stained cells.
VEGF-stimulated proliferation of CEC was inhibited by bevacizumab. Bevacizumab was not cytotoxic to human RPE and rat RGC in vitro at a dose that is inhibitory to monkey CEC.
评估血管内皮生长因子（VEGF）抗体贝伐单抗在体外对视网膜色素上皮细胞（RPE）和视网膜神经节细胞（RGC）的作用，所用剂量对富含 VEGF 的脉络膜内皮细胞（CEC）具有抑制作用。
将猴 CEC（RF6A）、人 RPE 细胞（ARPE-19）和大鼠 RGC（RGC-5）分别用不同浓度的贝伐单抗孵育 24 小时。通过 WST-1 测定法对细胞数量进行定量。通过流式细胞术和荧光显微镜使用碘化丙啶（PI）染色评估细胞死亡。
贝伐单抗在 2.0 mg/mL 时对 RF6A 具有抑制作用（P < 0.005）。在这个特定的贝伐单抗剂量下，对 ARPE-19 和 RGC-5 细胞系没有观察到细胞活力的影响。PI 染色荧光显微镜的结果支持了这一结论。
贝伐单抗抑制了 VEGF 刺激的 CEC 增殖。在抑制猴 CEC 的剂量下，贝伐单抗对体外培养的人 RPE 和大鼠 RGC 没有细胞毒性。
